The treatment of chronic hepatitis B: Focus on adefovir-like antivirals

References

• Aus dem SiepenMOniangue-NdzaCWieseM2007Interferon-alpha and ribavirin resistance of Huh7 cells transfected with HCV subgenomic repliconVirus Res1251091317254660
   PubMed Web of Science ®Google Scholar
• BerggrenSGallCWollnitzN2007Gene and protein expression of P-glycoprotein, MRP1, MRP2, and CYP3A4 in the small and large human intestineMol Pharm4252717263554
   PubMed Web of Science ®Google Scholar
• ChanCAbu-RaddadEGolorG2005Clinical pharmacokinetics of alamifovir and its metabolitesAntimicrob Agents Chemother4918132215855501
   PubMed Web of Science ®Google Scholar
• ChangTTGishRGde ManR2006A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis BN Engl J Med35410011016525137
   PubMed Web of Science ®Google Scholar
• ChenCJYangHISuJ2006REVEAL-HBV Study Group. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA levelJAMA295657316391218
   PubMed Web of Science ®Google Scholar
• ChoiJRChoDGRohKY2004A novel class of phosphonate nucleosides. 9-[(1-phosphonomethoxycyclopropyl)methyl]guanine as a potent and selective anti-HBV agentJ Med Chem472864915139764
   PubMed Web of Science ®Google Scholar
• ColonnoRJRoseREPokornowskiK2006Assessment at three years shows high barrier to resistance is maintained in entecavir-treated nucleoside naïve patients while resistance emergence increases over time in lamivudine refractory patientsHepatology4422930
   Web of Science ®Google Scholar
• CornbergMProtzerUDollingerMM2007Prophylaxis, diagnosis and therapy of hepatitis-B-virus-(HBV) infection: upgrade of the guideline. AWMF-Register 021/011Z Gastroenterol451287328
   Web of Science ®Google Scholar
• De ClercqE2007Anti-HIV drugsVerh K Acad Geneeskd Belg698110417550060
   PubMedGoogle Scholar
• de FranchisRHadengueALanGEASL Jury2003EASL International Consensus Conference on Hepatitis B. 13–14 September, 2002. Geneva, Switzerland. Consensus statementJ Hepatol3932512821036
   PubMed Web of Science ®Google Scholar
• Del PoggioPZaccanelliMOggionniM2007Low-dose tenofovir is more potent than adefovir and is effective in controlling HBV vire-mia in chronic HBeAg-negative hepatitis BWorld J Gastroenterol134096917696228
   PubMed Web of Science ®Google Scholar
• DienstagJLSchiffERWrightTL1999Lamivudine as initial treatment for chronic hepatitis B in the United StatesN Engl J Med34112566310528035
   PubMed Web of Science ®Google Scholar
• Gilead2007aPhase III Study evaluating Gilead’s Viread® for the treatment of chronic hepatitis B virus meets primary endpoint [online]. Accessed on May 28, 2008. URL:http://www.gilead.com/wt/sec/pr_1012569
   Google Scholar
• Gilead2007bSecond Phase III Study evaluating Gilead’s Viread® for the treatment of chronic hepatitis B virus meets primary endpoint [online]. Accessed on May 28, 2008. URL:http://www.gilead.com/wt/sec/pr_1018988
   Google Scholar
• HadziyannisSJTassopoulosNCHeathcoteEJ2003Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis BN Engl J Med348800712606734
   PubMed Web of Science ®Google Scholar
• HadziyannisSJTassopoulosNCHeathcoteEJ2005Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis BN Engl J Med35226738115987916
   PubMed Web of Science ®Google Scholar
• HadziyannisSJTassopoulosNCHeathcoteEJ2006Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 yearsGastroenterology13117435117087951
   PubMed Web of Science ®Google Scholar
• HanSLaiCGaneEJ2007Telbivudine globe trial at year two: efficacy, safety, and predictors of outcome in patients with chronic hepatitis BGastroenterology132765
   Web of Science ®Google Scholar
• HeathcoteEJGaneEDe ManRA Randomized, Double-Blind, Comparison of Tenofovir DF (TDF) Versus Adefovir Dipivoxil (ADV) for the Treatment of HBeAg Positive Chronic Hepatitis B (CHB): Study GS-US-174-0103Hepatology2007Suppl.1231A
   Google Scholar
• HeathcoteEJGeorgeJGordonSTenofovir Disoproxil Fumarate (TDF) for the treatment of HBeAg-positive chronic hepatitis B: Week 72 TDF data and week 24 Adefvoir Dipivoxil switch data (Study 103)J Hepatol2008Suppl.2S32
   Web of Science ®Google Scholar
• HezodeCChevaliezSBouvier-AliasM2007Efficacy and safety of adefovir dipivoxil 20 mg daily in HBeAg-positive patients with lamivudine-resistant hepatitis B virus and a suboptimal virological response to adefovir dipivoxil 10 mg dailyJ Hepatol46791617321635
   PubMed Web of Science ®Google Scholar
• IloejeUHYangHISuJRisk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer-In HBV (the REVEAL-HBV) Study Group. 2006. Predicting cirrhosis risk based on the level of circulating hepatitis B viral loadGastroenterology1306788616530509
   PubMed Web of Science ®Google Scholar
• IzzedineHHulotJSLaunay-VacherV2004Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studiesKidney Int661153815327411
   PubMed Web of Science ®Google Scholar
• JacquardACBrunelleMNPichoudC2006In vitro characterization of the anti-hepatitis B virus activity and cross-resistance profile of 2′,3′-dide-oxy-3′-fluoroguanosineAntimicrob Agents Chemother509556116495257
   PubMed Web of Science ®Google Scholar
• KahnJLagakosSWulfsohnM1999Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomized controlled trialJAMA2423051210612317
   PubMed Web of Science ®Google Scholar
• LaiCLShouvalDLokAS2006aEntecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis BN Engl J Med35410112016525138
   PubMed Web of Science ®Google Scholar
• LaiCLHanKHYoonSK2006bPhase II, multicentre, dose-escalating study of LB8030 (ANA380) in hepatitis B patients with lamivudine resistant YMDD mutant HBVJ Hepatol445
   Web of Science ®Google Scholar
• LauGKPiratvisuthTLuoKX2005Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis BN Engl J Med35226829515987917
   PubMed Web of Science ®Google Scholar
• LavanchyD2004Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measuresJ Viral Hepat119710714996343
   PubMed Web of Science ®Google Scholar
• LeeKSLimSGChuangWL2006Safety, tolerability and antiviral activity of pradefovir mesylate in patients with chronic hepatitis B virus infection: 48-week analysis of a phase 2 studyJ Hepatol44274
   Web of Science ®Google Scholar
• LiawYFLeungNGuanRAsian-Pacific Consensus Update Working Party on Chronic Hepatitis B2005Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 updateLiver Int254728915910483
   PubMed Web of Science ®Google Scholar
• LiawYFSungJJChowWCCirrhosis Asian Lamivudine Multicentre Study Group2004Lamivudine for patients with chronic hepatitis B and advanced liver diseaseN Engl J Med35115213115470215
   PubMed Web of Science ®Google Scholar
• LinCXuCYehLT2006Pharmacokinetics and pharmacodynamics of pradefovir mesylate, a liver-targeting pro-drug of PMEA, in HBV patientsJ Hepatol4416
   Web of Science ®Google Scholar
• LinCCYehLTVitarellaD2004Remofovir mesylate: A prodrug of PMEA with improved liver-targeting and safety in rats and monkeysAntivir Chem Chemother153071715646644
   PubMedGoogle Scholar
• LokASMcMahonBJ2007Chronic hepatitis BHepatology455073917256718
   PubMed Web of Science ®Google Scholar
• MarcellinPChangTTLimSG2003Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis BN Engl J Med3488081612606735
   PubMed Web of Science ®Google Scholar
• MarcellinPLauGKBoninoF2004Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis BN Engl J Med35112061715371578
   PubMed Web of Science ®Google Scholar
• MarcellinPButiMKrastevZA Randomized, Double-Blind, Comparison of Tenofovir DF (TDF) versus Adefovir Dipivoxil (ADV) for the Treatment of HBeAg-Negative Chronic Hepatitis B (CHB): Study GS-US-174-0102Hepatology2007Suppl.1231A
   Web of Science ®Google Scholar
• MarcellinPJacobsonIHabersetzerFTenofovir Disoproxil Fumarate (TDF) for the treatment of HBeAg-negative chronic hepatitis B: Week 72 TDF data and week 24 Adefvoir Dipivoxil switch data (Study 102)J Hepatol2008Suppl.2S26
   Web of Science ®Google Scholar
• McMahonMAJilekBLBrennanTP2007The HBV drug entecavir – effects on HIV-1 replication and resistanceN Engl J Med35626142117582071
   PubMed Web of Science ®Google Scholar
• PerzJFArmstrongGLFarringtonLA2006The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwideJ Hepatol455293816879891
   PubMed Web of Science ®Google Scholar
• PetersMGAndersenJLynchP2006Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127Hepatology441110617058225
   PubMed Web of Science ®Google Scholar
• RölingJSchmidHFischerederM2006HIV-associated renal diseases and highly active antiretroviral therapy-induced nephropathyClin Infect Dis4214889516619164
   PubMed Web of Science ®Google Scholar
• SheldonJCaminoNRodesB2005Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovirAntivir Ther107273416218172
   PubMed Web of Science ®Google Scholar
• SoonDKLoweSLTengCH2004Safety and efficacy of alamifovir in patients with chronic hepatitis B virus infectionJ Hepatol41852815519660
   PubMed Web of Science ®Google Scholar
• ThioCLLocarniniS2007Treatment of HIV/HBV coinfection: clinical and virologic issuesAIDS Rev9405317474312
   PubMed Web of Science ®Google Scholar
• TillmannHL2007Drug evaluation: Pradefovir, a liver-targeted prodrug of adefovir against HBV infectionCurr Opin Investig Drugs868290
   PubMedGoogle Scholar
• van BommelFBergT2005Reactivation of viral replication after replacement of tenofovir by adefovirHepatology422394015962310
   PubMed Web of Science ®Google Scholar
• van BommelFWunscheTMaussS2004Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infectionHepatology401421515565615
   PubMed Web of Science ®Google Scholar
• van BommelFZollnerBSarrazinC2006Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapyHepatology443182516871563
   PubMed Web of Science ®Google Scholar
• van der PoortenDPrakosoEKhooTL2007Combination adefovir-lamivudine prevents emergence of adefovir resistance in lamivudine-resistant hepatitis BJ Gastroenterol Hepatol221500517683493
   PubMed Web of Science ®Google Scholar
• YangHQiXSabogalAMillerMXiongSDelaneyWE4th2005Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBVAntivir Ther106253316152756
   PubMed Web of Science ®Google Scholar
• YouJZhuangLChengHY2006Efficacy of thymosin alpha-1 and interferon alpha in treatment of chronic viral hepatitis B: a randomized controlled studyWorld J Gastroenterol1267152117075991
   PubMed Web of Science ®Google Scholar
• YuenMFKimJKimCR2006A randomized placebo-controlled, dose-finding study of oral LB80380 in HBeAg-positive patients with chronic hepatitis BAntivir Ther119778317302367
   PubMed Web of Science ®Google Scholar